Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THERAPY WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
Autore:
STONE RM; BERNSTEIN SH; DEMETRI G; FACKLAM DP; ARTHUR K; ANDERSEN J; ASTER JC; KUFE D;
Indirizzi:
HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,44 BINNEY ST BOSTON MA 02115 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL BOSTON MA 02115
Titolo Testata:
Leukemia research
fascicolo: 10, volume: 18, anno: 1994,
pagine: 769 - 776
SICI:
0145-2126(1994)18:10<769:TWRIPW>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; CLINICAL-TRIAL; CIRCULATING ERYTHROPOIETIN; HUMAN INTERLEUKIN-3; ANEMIA; MARROW; DISORDERS; LEUKEMIA; CELLS;
Keywords:
ERYTHROPOIETIN; MYELODYSPLASTIC SYNDROMES; HEMATOPOIETIC GROWTH FACTORS; COLONY STIMULATING FACTORS; BONE MARROW FAILURE; ANEMIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
R.M. Stone et al., "THERAPY WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES", Leukemia research, 18(10), 1994, pp. 769-776

Abstract

We conducted a Phase I-II trial of recombinant human erythropoietin-beta (rhEPO) in patients with myelodysplastic syndrome (MDS). Patients with anemia and pathologically confirmed MDS were eligible for the study. Treatment consisted of rhEPO by subcutaneous injection thrice weekly for 6 weeks at one of three dose levels (100 U/kg (three patients),200 U/kg (three patients) and 400 U/kg (14 patients)). Ferrous sulfate (325 mg po tid) was also administered if the transferrin saturation was below 30% (two patients). Patients were monitored with weekly CBC,white cell differential, and reticulocyte counts. Bone marrow examinations were performed at the conclusion of the treatment period and after a 2 week wash-out period. Patients who responded to therapy were continued on rhEPO at the same dose for 6 additional months. Response criteria included: 50% reduction in transfusion requirements compared with the 6 week pre-study period; doubling of reticulocyte count that was maintained on two determinations at least 1 week apart; or an increase in hemoglobin by at least 1.2 gm/dl without transfusions. Pre-treatment factors potentially predictive of response were analyzed by univariate analysis and in a multivariate fashion by classification and regression trees. Seven of the twenty patients sustained an untransfused rise in serum hemoglobin greater than or equal to 1.2 gm/dl. Four of the sixteen patients (including three of seven patients experiencing a rise in serum hemoglobin) who were transfusion-dependent prior to the study achieved a reduction or elimination of their transfusion requirements. Five of thirteen patients who received rhEPO during the extension phase had a continued response. A low baseline erythropoietin level(<50 mU/ml) was the best predictor of hemoglobin response when controlling for other variables, rhEPO has a role in the treatment of certain patients with MDS, particularly in those whose endogenous serum erythropoietin levels are not markedly elevated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:19:18